Deep Track files Schedule 13G reporting 7.36M shares in ALMS (ALMS)
Deep Track Capital, Deep Track Biotechnology Master Fund, and David Kroin have jointly filed a Schedule 13G, reporting beneficial ownership of 7,362,035 shares of ALUMIS Inc. (ALMS). This represents 5.98% of the company's common stock as of April 7, 2026. The filing indicates shared voting and dispositive power over these shares, based on 123,139,425 shares outstanding as of March 12, 2026.
How this was made
The 30-second read
Why it matters
While ownership increased, without accompanying news or catalysts, immediate trading impact may be limited.
Market read
The filing suggests increased institutional interest, which could influence short-term trading dynamics.
What to watch
Market conditions, upcoming catalysts, and overall sector performance could overshadow ownership disclosures.
Background
Deep Track Capital and associated entities filed a Schedule 13G, indicating passive ownership of nearly 6% in ALMS.
Ticker impact
The filing indicates significant insider ownership, which could influence stock price movements.
Potential for moderate upward price movement due to increased institutional ownership, but limited immediate impact.
Ownership disclosure alone does not guarantee price movement; market reaction depends on broader context and investor perception.
Market effects
Potential positive sentiment in the biotech and life sciences sectors due to increased institutional interest.
Limited regional impact; primarily relevant to US markets where ALMS is listed.
Low; the news is company-specific and does not indicate broader global market shifts.
Counterpoint
Institutional ownership increase may be a passive move with limited impact; stock could remain range-bound.
Key entities
- Investment FirmDeep Track Capital
A prominent investment firm involved in biotech investments.
- CompanyALUMIS Inc.
A biotech company operating in the life sciences sector.
